Nicholas Hoffman & Company LLC. Sells 517 Shares of Eli Lilly and Company $LLY

Posted by Amy Steele on Jul 8th, 2026

Eli Lilly and Company logo Nicholas Hoffman & Company LLC. lowered its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 5.0% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 9,761 shares of the company’s stock after selling 517 shares during the period. Eli Lilly and Company comprises about 0.2% of Nicholas Hoffman & Company LLC.’s investment portfolio, making the stock its 28th biggest holding. Nicholas Hoffman & Company LLC.’s holdings in Eli Lilly and Company were worth $8,978,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. Aljian Capital Management LLC boosted its position in Eli Lilly and Company by 48.6% in the first quarter. Aljian Capital Management LLC now owns 1,811 shares of the company’s stock worth $1,665,000 after purchasing an additional 592 shares during the last quarter. Eads & Heald Wealth Management increased its position in shares of Eli Lilly and Company by 34.2% during the 1st quarter. Eads & Heald Wealth Management now owns 1,220 shares of the company’s stock valued at $1,122,000 after purchasing an additional 311 shares during the last quarter. Jackson Thornton Wealth Management LLC lifted its stake in shares of Eli Lilly and Company by 3.3% in the 1st quarter. Jackson Thornton Wealth Management LLC now owns 1,413 shares of the company’s stock worth $1,327,000 after purchasing an additional 45 shares during the period. Addison Capital Co lifted its stake in shares of Eli Lilly and Company by 18.8% in the 1st quarter. Addison Capital Co now owns 2,270 shares of the company’s stock worth $2,088,000 after purchasing an additional 360 shares during the period. Finally, Fishman Jay A Ltd. MI boosted its holdings in shares of Eli Lilly and Company by 9.7% in the first quarter. Fishman Jay A Ltd. MI now owns 30,866 shares of the company’s stock worth $28,390,000 after buying an additional 2,727 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

LLY opened at $1,233.32 on Wednesday. The company has a 50 day simple moving average of $1,078.08 and a two-hundred day simple moving average of $1,030.27. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The firm has a market cap of $1.16 trillion, a P/E ratio of 43.81, a PEG ratio of 1.49 and a beta of 0.51. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,249.45.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. During the same period last year, the firm earned $3.34 EPS. The company’s revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities analysts forecast that Eli Lilly and Company will post 35.74 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 24.58%.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

Positive Sentiment: JPMorgan raised its price target on Eli Lilly to $1,400 from $1,300 and reiterated an overweight rating, signaling continued upside expectations for the stock. Benzinga report on JPMorgan price target raise
Positive Sentiment: Shares hit a fresh 52-week high, reflecting momentum buying and strong investor enthusiasm around Lilly’s GLP-1 and obesity-treatment pipeline. CNBC report on Eli Lilly hitting 52-week high
Positive Sentiment: Weak results from Kailera Therapeutics’ weight-loss pill IPO appear to have indirectly helped Lilly by reinforcing the market’s confidence in Lilly’s lead position in obesity drugs. Yahoo Finance article on Kailera setback and Lilly market cap
Positive Sentiment: Commentary from Jim Cramer and other market-watch pieces remained constructive on biotech and Lilly’s growth story, suggesting investors still see the company as a core winner in the GLP-1 boom. 247WallSt Cramer commentary on Eli Lilly
Neutral Sentiment: Several articles highlighted Lilly as a top healthcare stock to own and as a long-term growth story, but these were mainly opinion pieces rather than new company-specific developments. Motley Fool article on Eli Lilly stock
Neutral Sentiment: Recent partnership and China-related business updates show Lilly is still actively managing its broader pipeline and regional strategy, but they appear less important than the obesity franchise news for today’s move. Yahoo Finance article on R&D collaboration and China rights transfer
Negative Sentiment: Some coverage continues to point to regulatory and pricing-policy risks for Lilly, which could weigh on sentiment over time even as the stock remains strong now. Yahoo Finance article on regulatory and pricing policy challenges

Analyst Upgrades and Downgrades

LLY has been the subject of a number of research reports. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a report on Monday, June 8th. Wall Street Zen raised shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 2nd. Bank of America upped their price objective on Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the stock a “buy” rating in a research note on Tuesday, May 26th. Barclays raised their target price on Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an “overweight” rating in a report on Monday, May 4th. Finally, Jefferies Financial Group lifted their target price on Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a “buy” rating in a research report on Tuesday, June 9th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,243.22.

Check Out Our Latest Stock Analysis on LLY

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.